Literature DB >> 29230534

The Burden of Comorbidity and Complexity in Sarcoidosis: Impact of Associated Chronic Diseases.

Pilar Brito-Zerón1,2, Nihan Acar-Denizli3, Antoni Sisó-Almirall4, Xavier Bosch5, Fernanda Hernández6, Sergi Vilanova4, Mireia Villalta4, Belchin Kostov4, Marina Paradela7, Marcelo Sanchez8, José Ramírez9, Africa Muxí10, Antonio Berruezo11, Celeste Galceran-Chaves12, Antoni Xaubet6, Carles Agustí6, Jacobo Sellarés6, Manuel Ramos-Casals13.   

Abstract

PURPOSE: To evaluate comorbidity, complexity and poor outcomes in patients with sarcoidosis and to compare those scores with a control group.
METHODS: 218 consecutive patients were diagnosed with sarcoidosis according to the ATS/ERS/WASOG criteria; extrathoracic involvement was evaluated using the 2014 WASOG organ assessment instrument. Sarcoidosis patients were compared with an age- and gender-matched control group of primary care outpatients without sarcoidosis. Comorbidities were assessed retrospectively using the Charlson Comorbidity Index (CCI); complexity was evaluated according to the classification into Clinical Risk Groups (CRG) and severity levels.
RESULTS: The cohort included 142 women and 76 men; the mean age was 47.1 years at diagnosis of sarcoidosis and 55.9 years at the last visit. Patients with a CCI > 1 had a higher frequency of calcium/vitamin D abnormalities (p < 0.001), kidney involvement (p = 0.005) and a higher mortality rate (p < 0.001) compared with patients with a CCI ≤ 1. Patients with a CRG ≥ 6 had a higher frequency of extrathoracic involvement (p = 0.039), calcium/vitamin D abnormalities (p = 0.019) and treatment with glucocorticoids (p = 0.032) compared with patients with a CRG < 6. 11% patients died after a mean follow-up of 102.3 months. Country of birth, kidney involvement and extrathoracic disease were significantly associated with death. Patients with sarcoidosis had a higher frequency of liver (p < 0.001), pulmonary (p = 0.002) and autoimmune disease (p = 0.011) and cancer (p = 0.007) compared with the control group.
CONCLUSION: We found higher rates of comorbidity and complexity in patients with sarcoidosis compared with a control group. Liver, pulmonary, autoimmune and neoplastic diseases were the main comorbidities found in patients with sarcoidosis.

Entities:  

Keywords:  Clinical Risk Groups; Comorbidity; Complexity; Sarcoidosis

Mesh:

Year:  2017        PMID: 29230534     DOI: 10.1007/s00408-017-0076-4

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  46 in total

1.  Main causes and risk factors for hospitalisation in patients with primary Sjögren's syndrome.

Authors:  Yemil Atisha-Fregoso; Yahaira Rivera-Vicencio; Miguel Baños-Pelaez; Gabriela Hernández-Molina
Journal:  Clin Exp Rheumatol       Date:  2015-08-27       Impact factor: 4.473

2.  What comorbidities accompany sarcoidosis? A large cohort (n=1779) patients analysis.

Authors:  Magdalena M Martusewicz-Boros; Piotr W Boros; Elżbieta Wiatr; Kazimierz Roszkowski-Śliż
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2015-07-22       Impact factor: 0.670

3.  Epidemiologic patterns of disease expression in sarcoidosis: age, gender and ethnicity-related differences.

Authors:  Pilar Brito-Zerón; Jacobo Sellarés; Xavier Bosch; Fernanda Hernández; Belchin Kostov; Antoni Sisó-Almirall; Carlos Lopez Casany; Josep Manel Santos; Marina Paradela; Marcelo Sánchez; José Ramírez; Antoni Xaubet; Carles Agustí; Manuel Ramos-Casals
Journal:  Clin Exp Rheumatol       Date:  2016-04-06       Impact factor: 4.473

Review 4.  How are cancer and connective tissue diseases related to sarcoidosis?

Authors:  Amit Chopra; Marc A Judson
Journal:  Curr Opin Pulm Med       Date:  2015-09       Impact factor: 3.155

Review 5.  Clinical phenotypes in sarcoidosis.

Authors:  Carlos A C Pereira; Marina C Dornfeld; Robert Baughman; Marc A Judson
Journal:  Curr Opin Pulm Med       Date:  2014-09       Impact factor: 3.155

Review 6.  Morbidity and mortality in sarcoidosis.

Authors:  Alicia K Gerke
Journal:  Curr Opin Pulm Med       Date:  2014-09       Impact factor: 3.155

7.  Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus.

Authors:  A Jönsen; A E Clarke; L Joseph; P Belisle; S Bernatsky; O Nived; A A Bengtsson; G Sturfelt; C A Pineau
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-09       Impact factor: 4.794

Review 8.  Corticosteroids in Sarcoidosis.

Authors:  Marc A Judson
Journal:  Rheum Dis Clin North Am       Date:  2015-10-26       Impact factor: 2.670

Review 9.  Airway involvement in sarcoidosis.

Authors:  Vlassis S Polychronopoulos; Udaya B S Prakash
Journal:  Chest       Date:  2009-11       Impact factor: 9.410

10.  In-Hospital Disease Burden of Sarcoidosis in Switzerland from 2002 to 2012.

Authors:  Susanne Pohle; Florent Baty; Martin Brutsche
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

View more
  10 in total

1.  The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.

Authors:  Monica S Thakar; Larisa Broglie; Brent Logan; Andrew Artz; Nancy Bunin; Lauri M Burroughs; Caitrin Fretham; David A Jacobsohn; Alison W Loren; Joanne Kurtzberg; Caridad A Martinez; Shin Mineishi; Adam S Nelson; Ann Woolfrey; Marcelo C Pasquini; Mohamed L Sorror
Journal:  Blood       Date:  2018-12-13       Impact factor: 22.113

2.  Hypercalciuria may predict better response to immunosuppressive therapy in renal sarcoidosis: a case series.

Authors:  Tao Zhao; Xiaojuan Yu; Suxia Wang; Li Yang; Tao Su
Journal:  J Nephrol       Date:  2022-06-13       Impact factor: 3.902

3.  Sarcoidosis and increased risk of comorbidities and mortality in sweden.

Authors:  Johanna Larsson; Pål Graff; Ing-Liss Bryngelsson; Per Vihlborg
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-06-30       Impact factor: 0.670

4.  The incidence, comorbidity and mortality of sarcoidosis in Korea, 2008-2015: a nationwide population-based study.

Authors:  Mi Hye Jeon; Taeuk Kang; Sang Hoon Yoo; Heather S Swan; Hyun Jung Kim; Hyeong Sik Ahn
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-03-15       Impact factor: 0.670

5.  First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative.

Authors:  Nynke A Kampstra; Jan C Grutters; Frouke T van Beek; Daniel A Culver; Robert P Baughman; Elisabetta A Renzoni; Wim Wuyts; Vaslis Kouranos; Marlies S Wijsenbeek; Douwe H Biesma; Philip J van der Wees; Paul B van der Nat
Journal:  BMJ Open Respir Res       Date:  2019-02-18

Review 6.  Comprehensive Care for Patients with Sarcoidosis.

Authors:  Catharina C Moor; Vivienne Kahlmann; Daniel A Culver; Marlies S Wijsenbeek
Journal:  J Clin Med       Date:  2020-02-01       Impact factor: 4.241

7.  Type 2 diabetes risk in sarcoidosis patients untreated and treated with corticosteroids.

Authors:  Joshua P Entrop; Susanna Kullberg; Johan Grunewald; Anders Eklund; Kerstin Brismar; Elizabeth V Arkema
Journal:  ERJ Open Res       Date:  2021-05-24

8.  Elderly Onset Sarcoidosis: A Case Report.

Authors:  Lintu Ramachandran; Saagar Pamulapati; Aisha Barlas; Ammar Aqeel
Journal:  Cureus       Date:  2021-12-15

Review 9.  A Comprehensive Review of Sarcoidosis Diagnosis and Monitoring for the Pulmonologist.

Authors:  Andrea S Melani; Albano Simona; Martina Armati; Miriana d'Alessandro; Elena Bargagli
Journal:  Pulm Ther       Date:  2021-06-06

Review 10.  A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists.

Authors:  Andrea S Melani; Caterina Bigliazzi; Flora Anna Cimmino; Laura Bergantini; Elena Bargagli
Journal:  Pulm Ther       Date:  2021-06-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.